targets connections between nerve cells( the pallidothalamic tract) rather than the nerve cells themselves— picture cutting a wire, instead of turning off all the lights. Benefits are typically immediate, but the procedure is irreversible.
Accelerating Discovery through De-Risking Targets for Precision Therapies
A critical part of our Q & A work at the Foundation
is ensuring a diverse therapeutic pipeline for Parkinson’ s disease, one that is continually seeded, re-seeded and refreshed with new opportunities to explore Parkinson’ s biology and discover the next generation of treatments.
One example of this approach is Targets to Therapies, a program fostering collaboration and partnership across academia, industry and the clinic, where researchers aim to accelerate the pipeline by identifying and shining a light on unexplored drug targets( the biology that treatments home in on). These targets stem
Shalini Padmanabhan, PhD from efforts across the field, including rich inputs from MJFF research program datasets and collaboration with Aligning Sciences Across Parkinson’ s( ASAP) initiative-supported programs like the Parkinson’ s Progression Markers Initiative( PPMI).
Shalini Padmanabhan, PhD, senior vice president of discovery and translational research at MJFF, explains.
18